Annelise Vuidepot
Chief Science & Technology Officer Immunocore
Annelise joined Immunocore when it was founded (as Avidex) in 2000 and has played a lead role in the design and engineering of the ImmTAX platform, pioneering a novel class of TCR based therapeutics.
She is currently leading Immunocore’s drug discovery pipeline and research to expand the ImmTAX technology further. She is also Immunocore’s UK Site Head.
Before joining Immunocore, Annelise was a postdoctoral researcher in the Biochemistry department at University College London. She gained her master’s degree in chemistry from the University of Paris and her PhD in Biophysics from the École Polytechnique in Saclay, France.
Seminars
Tuesday 19th May 2026
Expanding the Potential of TCR-Based T-Cell Engagers into Infectious Diseases
10:00 am
- Sharing early clinical data on TCR-based bispecific molecules developed to treat HBV and HIV
- Analyzing the pharmacokinetics and pharmacodynamics associated with this mechanism of action
- Highlighting the differences from oncology that emerge due to a lack of suppressive tumor microenvironment
New Data
Tuesday 19th May 2026
C-Level Fireside Chat: Reflecting on Lessons from TCR Therapies to Drive Next-Generation Strategies
9:00 am
- Identifying pivotal learnings that can sharpen development strategies and accelerate stronger clinical outcomes
- Framing actionable insights that translate early proof-of-concept gains into durable, real-world clinical impact
- Exploring critical knowledge gaps and defining high-value priorities that can shape the next-generation of TCR innovations
